Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK131 in advanced solid tumors
NCT06166888Phase 1Recruiting
- Sponsor
- Akeso, Inc.
- Start
- Jan 2024
- Primary completion
- Aug 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AK131 in solid tumor, sponsored by Akeso, Inc. Primary endpoints: Number of subjects with dose limiting toxicities at 4 weeks and Number of subjects with adverse events. Started Jan 2024; status: recruiting.
02
Drugs
AK131
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06166888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06166888.